AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Weaponizing Immune Cells with New Liposomes to Target Metastatic Cancer

Detailed Technology Description
Thisinvention describes a method to functionalized cells using liposomenanoparticles for inhibiting metastatic cancer cells.
Others

 

*Abstract

Circulating blood cells are functionalized directly in vivo, which then adhere to circulating tumor, immune, or other cells for the treatment of metastasis, inflammation, and other conditions.

 

In one embodiment, Cornell researchers have used this approach to capture and kill circulating tumor cells (CTC) in blood and lymphatic vessels. Leukocytes were functionalized with TRAIL-decorated liposome nanoparticles. These leukocytes, bound to CTC, then induce apoptosis, thereby eliminating CTC from circulation.

Since greater than 90% of cancer related deaths are caused by metastasis, this technology offers a potentially important treatment in an area of significant and unmet need.

Additional potential applications for this approach include use of other decorated nanoparticles for various types of cancer treatment, as well as for anti-inflammatory conditions. A further utilization of this technology involves its use in imaging techniques.

 

Potential Commercial Applications:

  • Treatment for highly metastatic cancers such as breast, prostate, and lung cancer
  • Treatment for inflammation

 

Advantages

Representsa major breakthrough in cancer treatment, as there are no existing technologiesthat can both capture and kill CTC in vivo.

*Licensing
Jeff Fearnjcf55@cornell.edu607-254-4502
Country/Region
USA

For more information, please click Here
Mobile Device